Uncertainty And Variability In Physiologically-Based Pharmacokinetic (PBPK) Models: Key Issues And Case Studies (Final Report)

IRIS

Methyl tert-butyl ether (MTBE)

CASRN 1634-04-4 | DTXSID3020833

IRIS Summary (PDF) (25 pp, 166.0 KB)

On this page:

Overview
Background
Downloads

Overview

EPA announced the availability of the final report, Uncertainty and Variability in Physiologically-Based Pharmacokinetic (PBPK) Models: Key Issues and Case Studies. This report summarizes some of the recent progress in characterizing uncertainty and variability in physiologically-based pharmacokinetic models and their predictions for use in risk assessment.

Citation

U.S. EPA. Uncertainty And Variability In Physiologically-Based Pharmacokinetic (PBPK) Models: Key Issues And Case Studies (Final Report). U.S. Environmental Protection Agency, Washington, DC, EPA/600/R-08/090.

Top of Page

Background

Chemical risk and safety assessments increasingly rely upon tissue dosimetry estimates in animals and humans obtained from physiologically-based pharmacokinetic (PBPK) modeling. However, risk assessment also increasingly requires characterization of uncertainty and variability; such characterization for PBPK model predictions represents a continuing challenge to both modelers and users.

Current practices show significant progress in specifying deterministic biological models and the non-deterministic (often statistical) models, estimating their parameters using diverse data sets from multiple sources, and using them to make predictions and characterize uncertainty and variability. This report summarizes some of the recent progress in this area that has been conducted or supported by the National Center for Environmental Assessment (NCEA). These include the identification of the state-of-the science on key issues in this area, as well as priority research or implementation needs. In addition, a number of case examples of chemical-specific applications have demonstrated some of the methods and issues associated with characterizing uncertainty and variability in PBPK modeling.

History/Chronology

Date	Description
01- Oct 2006	Case studies using tetrachloroethylene and route-to-route extrapolation completed.
02- Oct/Nov 2006	EPA hosted an International Workshop on Uncertainty and Variability in PBPK Models.
03- Apr 2007	Case study on methyl tertiary butyl ether was published.
04- Sep 2007	Case study using 1,3-butadiene was published.
05- Sep 2008	EPA released the final report.

Top of Page

Download(s)

This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.

Uncertainty and Variability in Physiologically-Based Pharmacokinetic Models: Key Issues and Case Studies (PDF) (10 pp, 66.4 KB, about PDF)

If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact Us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.